In this article, we will discuss Palonosetron and Moderately Emetogenic Chemotherapy. So, let’s get started.
Palonosetron and Moderately Emetogenic Chemotherapy
Two double-blind trials (Study 1 and Study 2) involving 1,132 patients compared a single intravenous dose of palonosetron HCl with either a single intravenous dose of
ondansetron (Study 1) or dolasetron (Study 2) given 30 minutes prior to moderately
emetogenic chemotherapy including carboplatin, cisplatin ≤ 50 mg/m²,
cyclophosphamide < 1,500 mg/m², doxorubicin > 25 mg/m², epirubicin, irinotecan, and methotrexate > 250 mg/m². Concomitant corticosteroids were not administered prophylactically in Study 1 and were only used by 4 to 6% of patients in Study 2. The majority of patients in these studies were women (77%), White (65%) and naïve to previous chemotherapy (54%). The mean age was 55 years.